For research use only. Not for therapeutic Use.
Mopivabil（Cat No.:I045085）is an investigational, long-acting IL-4 receptor alpha antagonist designed to inhibit signaling pathways shared by interleukin-4 and interleukin-13, key drivers of type 2 inflammation. Developed for conditions like asthma, atopic dermatitis, and other allergic diseases, Mopivabil blocks the IL-4Rα subunit, reducing inflammation, mucus production, and immune cell activation. Its extended half-life allows for less frequent dosing compared to existing biologics. As a next-generation biologic, Mopivabil aims to offer improved efficacy and patient compliance in managing chronic inflammatory disorders characterized by elevated type 2 immune responses.
| CAS Number | 2988562-84-9 |
| Synonyms | (4-ethyl-2-methoxyphenyl) 2,2-dimethylpropanoate |
| Molecular Formula | C14H20O3 |
| Purity | ≥95% |
| IUPAC Name | (4-ethyl-2-methoxyphenyl) 2,2-dimethylpropanoate |
| InChI | InChI=1S/C14H20O3/c1-6-10-7-8-11(12(9-10)16-5)17-13(15)14(2,3)4/h7-9H,6H2,1-5H3 |
| InChIKey | ZITQYHHKBYAVSF-UHFFFAOYSA-N |
| SMILES | CCC1=CC(=C(C=C1)OC(=O)C(C)(C)C)OC |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
